Friday, May 1, 2015

MyoKardia Finds $46M For Treating Genetic Heart Disease

South San Francisco-based MyoKardia, which is developing treatments for genetics-related heart disease, said yesterday that it has raised $46M in a Series B funding. The funding came from an un-named public investment fund, Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences, an affiliate of Cowen Group, and BridgeBio LLC, along with others. MyoKardia, which is led by Tassos Gianakakos, is developing treatments for hypertrophic and dilated cardiomyopathies (HCM and DCM). More information »